These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 34611409)

  • 1. Identification of a Novel SLC8A1-ALK Fusion and Non-Canonical Expression Significantly Responding to ALK-TKIs in Lung Adenocarcinoma: A Case Report.
    Zhu X; He Y; Wang Y; Lei Y; Su X; Liu Y; Wu S; He Z
    Onco Targets Ther; 2021; 14():4915-4920. PubMed ID: 34611409
    [TBL] [Abstract][Full Text] [Related]  

  • 2. An Anaplastic Lymphoma Kinase Immunohistochemistry-Negative but Fluorescence In Situ Hybridization-Positive Lung Adenocarcinoma Is Resistant to Crizotinib.
    Shi R; Varella-Garcia M; Li M; Ludkovski O; Danesh A; Ng C; Pham NA; Pugh T; Shepherd FA; Tsao MS
    J Thorac Oncol; 2016 Dec; 11(12):2248-2252. PubMed ID: 27613526
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A rare KIF5B-ALK fusion variant in a lung adenocarcinoma patient who responded to crizotinib and acquired the ALK L1196M mutation after resistance: a case report.
    Zeng H; Liu Y; Wang W; Tang Y; Tian P; Li W
    Ann Palliat Med; 2021 Jul; 10(7):8352-8357. PubMed ID: 33832282
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Treatment Sequencing in Patients with Anaplastic Lymphoma Kinase-Positive Non-Small Cell Lung Cancer in Japan: A Real-World Observational Study.
    Goto Y; Yamamoto N; Masters ET; Kikkawa H; Mardekian J; Wiltshire R; Togo K; Ohe Y
    Adv Ther; 2020 Jul; 37(7):3311-3323. PubMed ID: 32472430
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A novel
    Deng L; Tian P; Qiu Z; Wang K; Li Y
    Open Life Sci; 2022; 17(1):846-850. PubMed ID: 36045716
    [No Abstract]   [Full Text] [Related]  

  • 6. CUX1-ALK, a Novel ALK Rearrangement That Responds to Crizotinib in Non-Small Cell Lung Cancer.
    Zhang M; Wang Q; Ding Y; Wang G; Chu Y; He X; Wu X; Shao YW; Lu K
    J Thorac Oncol; 2018 Nov; 13(11):1792-1797. PubMed ID: 30010043
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Impact of ALK Inhibitors in Patients With
    Takeyasu Y; Okuma HS; Kojima Y; Nishikawa T; Tanioka M; Sudo K; Shimoi T; Noguchi E; Arakawa A; Mori T; Sunami K; Kubo T; Kohno T; Akihiko Y; Yamamoto N; Yonemori K
    JCO Precis Oncol; 2021; 5():. PubMed ID: 34036223
    [TBL] [Abstract][Full Text] [Related]  

  • 8. STK3-ALK, a Novel ALK Rearrangement in Non-Small Cell Lung Cancer With Sensitivity to Tyrosine Kinase Inhibitors: A Case Report.
    Feng C; Zhou R; Liu F; Wang T; Liu S; Shao Y
    Front Oncol; 2021; 11():700341. PubMed ID: 34490099
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Molecular characteristics and clinical outcomes of complex ALK rearrangements identified by next-generation sequencing in non-small cell lung cancers.
    Xia P; Zhang L; Li P; Liu E; Li W; Zhang J; Li H; Su X; Jiang G
    J Transl Med; 2021 Jul; 19(1):308. PubMed ID: 34271921
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical outcomes in ALK-rearranged lung adenocarcinomas according to ALK fusion variants.
    Cha YJ; Kim HR; Shim HS
    J Transl Med; 2016 Oct; 14(1):296. PubMed ID: 27756333
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Novel MRPS9-ALK Fusion Mutation in a Lung Adenocarcinoma Patient: A Case Report.
    Zhou H; Xu B; Xu J; Zhu G; Guo Y
    Front Oncol; 2021; 11():670907. PubMed ID: 34168990
    [TBL] [Abstract][Full Text] [Related]  

  • 12. LMO7-ALK Fusion in a Lung Adenocarcinoma Patient With Crizotinib: A Case Report.
    Yang Y; Zheng H; Li Z; Shi S; Zhong L; Gong L; Lan B
    Front Oncol; 2022; 12():841493. PubMed ID: 35664754
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Anaplastic lymphoma kinase immunoreactivity correlates with ALK gene rearrangement and transcriptional up-regulation in non-small cell lung carcinomas.
    Boland JM; Erdogan S; Vasmatzis G; Yang P; Tillmans LS; Johnson MR; Wang X; Peterson LM; Halling KC; Oliveira AM; Aubry MC; Yi ES
    Hum Pathol; 2009 Aug; 40(8):1152-8. PubMed ID: 19386350
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Use of ALK Immunohistochemistry for Optimal Therapeutic Strategy of Pulmonary Large-cell Neuroendocrine Carcinoma and Identification of a Novel
    Shimizu N; Akashi Y; Fujii T; Shiono H; Yane K; Kitahara T; Ohta Y; Kakudo K; Wakasa T
    Anticancer Res; 2019 Jan; 39(1):413-420. PubMed ID: 30591488
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Treatment Optimization for Brain Metastasis from Anaplastic Lymphoma Kinase Rearrangement Non-Small-Cell Lung Cancer.
    Wang W; Sun X; Hui Z
    Oncol Res Treat; 2019; 42(11):599-606. PubMed ID: 31527380
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A novel
    Pan X; Zhong A; Xing Y; Li X; Du H; Shi M
    J Int Med Res; 2021 Sep; 49(9):3000605211044652. PubMed ID: 34590916
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Detection of ALK rearrangement by immunohistochemistry in lung adenocarcinoma and the identification of a novel EML4-ALK variant.
    To KF; Tong JH; Yeung KS; Lung RW; Law PP; Chau SL; Kang W; Tong CY; Chow C; Chan AW; Leung LK; Mok TS
    J Thorac Oncol; 2013 Jul; 8(7):883-91. PubMed ID: 23625156
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Anaplastic lymphoma kinase (ALK)-expressing Lung Adenocarcinoma with Combined Neuroendocrine Component or Neuroendocrine Transformation: Implications for Neuroendocrine Transformation and Response to ALK-tyrosine Kinase Inhibitors.
    Sim J; Kim H; Hyeon J; Choi Y; Han J
    J Korean Med Sci; 2018 Apr; 33(15):e123. PubMed ID: 29629521
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Responses to crizotinib in patients with ALK-positive lung adenocarcinoma who tested immunohistochemistry (IHC)-positive and fluorescence in situ hybridization (FISH)-negative.
    Ma D; Wang Z; Yang L; Mu X; Wang Y; Zhao X; Li J; Lin D
    Oncotarget; 2016 Sep; 7(39):64410-64420. PubMed ID: 27418132
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Detecting ALK Rearrangement with RT-PCR: A Reliable Approach Compared with Next-Generation Sequencing in Patients with NSCLC.
    Kuang Y; Xu P; Wang J; Zheng Y; Sun X; Li Z; Gan R; Li H; Guo Y; Yao F; Zhu C; Ke Z; Tang K
    Mol Diagn Ther; 2021 Jul; 25(4):487-494. PubMed ID: 34133003
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.